Abstract
In Japan, the choice of anti-diabetic medication is officially recommended according to the patient's glycemic condition and disease phenotype, unlike most other regions where metformin is recommended as the first-line medication. There has been an increase in the number of available glucose-lowering agents, making it necessary to select these agents based on ever-improving evidence obtained from clinical trials. For the dipeptidyl peptidase-4 inhibitor class of drugs, nine drugs are currently available on the market in Japan. Although previous cardiovascular outcome trials (CVOTs) demonstrated non-inferiority for both major adverse cardiovascular events (MACEs) and safety for some drugs of the class, the design and results of the CARMELINA trial seemed to be slightly different from earlier trials in that it showed the drugs were safe and partially effective even in patients with renal impairment. Thus, recent CVOTs on newer glucose-lowering agents have mainly focused on the major impacts of individual classes and drugs on clinical outcomes behind their glucose-lowering action. The diverse features of the classes and individual drugs may have also highlighted not only the class-effects, but also the drug-effects of glucose-lowe...Continue Reading
References
Sep 3, 2013·The New England Journal of Medicine·Benjamin M SciricaUNKNOWN SAVOR-TIMI 53 Steering Committee and Investigators
Sep 13, 2013·Diabetes Care·Per-Henrik GroopMaximilian von Eynatten
Mar 18, 2015·Diabetes & Vascular Disease Research : Official Journal of the International Society of Diabetes and Vascular Disease·Nikolaus MarxHans-Juergen Woerle
Dec 17, 2015·Journal of the American College of Cardiology·Stuart J PocockTim J Collier
Feb 19, 2016·BMJ : British Medical Journal·Ling LiXin Sun
Jan 23, 2017·Cardiovascular Diabetology·Thomas JaxNikolaus Marx
Feb 11, 2018·Heart and Vessels·Taku KoyamaKoichi Node
Apr 20, 2018·Cardiovascular Diabetology·Annayya R AroorVincent G DeMarco
May 12, 2018·Circulation Research·André J Scheen
May 19, 2018·Cardiovascular Diabetology·Norbert J TripoltHarald Sourij
Sep 28, 2018·Current Cardiology Reports·Yixing Li, Paul D Rosenblit
Nov 13, 2018·JAMA : the Journal of the American Medical Association·Julio RosenstockUNKNOWN CARMELINA Investigators
Nov 15, 2018·Lancet·Thomas A ZelnikerMarc S Sabatine
Dec 28, 2018·Circulation·Darren K McGuireUNKNOWN CARMELINA Investigators
Citations
Nov 11, 2019·Cardiovascular Diabetology·Ya-Ru WuJian-Jun Li
Feb 13, 2021·Cardiovascular Diabetology·Atsushi Tanaka, Koichi Node
May 16, 2021·Hypertension Research : Official Journal of the Japanese Society of Hypertension·Atsushi Tanaka, Koichi Node